Article: Orbus Pharma Inc. Announces Signing of a Three Way License, Sale of Marketing Authorisations and Manufacturing Agreement

TORONTO, ONTARIO--(CCNMatthews - Nov. 6, 2006) - Orbus Pharma Inc. (TSX:ORB) ("Orbus") today announced that it has entered into an agreement with Desitin Arzneimittel GmbH, ("Desitin") of Germany for its immediate release 150mg, 300mg and 600mg tablets containing the active ingredient oxcarbazepine (anti-epileptic). Also party to the agreement is Orbus' partner in this drug development, Alfred E.Tiefenbacher GmbH & Co. KG ("AET") of Germany.

The agreement provides for the ongoing relationship between Orbus, AET and Desitin to utilize Orbus' immediate release Oxcarbazepine formulations to obtain marketing authorizations throughout the European Union, as well as in Switzerland, Romania, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!